The Consolidation Wave in Pharma Supply Chains: What 2026 Means for Manufacturers

The original SCW article on pharma supply chain consolidation framed 2025 as a year of major deals, driven by efficiency, compliance, resilience, and technology integration. That direction still holds, but by the end of 2026, the story has become more specific and more urgent for pharma manufacturers.

Why Pharma Supply Chain Consolidation Is Accelerating in 2026

Pharma supply chains are under pressure from several directions at once. Manufacturers need more specialized capacity for biologics, peptides, cell and gene therapies, GLP-1 products, sterile manufacturing, and cold chain distribution. At the same time, regulators and policymakers are pushing for stronger supply resilience, better shortage prevention, and more regional manufacturing capacity.

Market signals confirm the same direction. PwC’s 2026 midyear pharma and life sciences deals outlook says deal momentum is strong, broad, and set to continue into the second half of 2026. PwC’s global health industries outlook also notes that global health industries M&A in the first five months of 2026 included a return of megadeal activity.

EY’s 2026 Firepower report adds another important point: life sciences companies still have major dealmaking capacity, with EY describing record firepower of about $2.1 trillion across the sector. That means consolidation pressure is likely to continue, especially where companies need scale, new capabilities, and faster access to growth platforms.

For a pharma manufacturer, the implication is practical. Consolidation changes who controls capacity, where risk sits, how partners prioritize customers, and how easily data can flow across the network.

Where Consolidation Is Happening Across the Pharma Supply Chain

CDMO and Manufacturing Capacity Consolidation

The most visible consolidation theme is manufacturing capacity. Novo Holdings completed its approximately $16.5 billion acquisition of Catalent in December 2024, and Novo Nordisk completed the related acquisition of three manufacturing sites from Novo Holdings. Novo Nordisk stated that the sites would expand manufacturing capacity at scale and speed.

Lonza completed its acquisition of Roche’s Genentech large-scale biologics site in Vacaville, California for $1.2 billion, strengthening its ability to support large-scale, end-to-end manufacturing of complex biologics.

By 2026, the trend had moved into additional modalities. Samsung Biologics announced an all-cash offer to acquire PolyPeptide, a specialized global CDMO for peptide-based active pharmaceutical ingredients. The transaction values PolyPeptide equity at approximately CHF 1.46 billion, and Samsung positioned the move as a way to expand its global network across the U.S., Europe, and India.

For manufacturers, these moves mean that critical capacity is increasingly concentrated in fewer, larger networks.

Distribution and Specialty Care Consolidation

Consolidation is also changing distribution and specialty access. McKesson completed its acquisition of a controlling interest in Core Ventures for about $2.49 billion, strengthening its oncology platform. Cardinal Health completed its acquisition of Integrated Oncology Network for approximately $1.1 billion.

Cencora agreed to merge MWI Animal Health with Covetrus in a transaction valuing MWI at $3.5 billion, allowing Cencora to sharpen its focus on its core human health and drug distribution business.

This matters because distribution is no longer only about moving product. Large distributors are becoming more connected to specialty care sites, data services, patient access, and commercialization pathways.

Cold Chain and Logistics Consolidation

Cold chain logistics is becoming a strategic asset. DHL Group acquired CRYOPDP from Cryoport in 2025 to strengthen specialized pharma logistics for clinical trials, biopharma, and cell and gene therapies. DHL Supply Chain also completed its acquisition of SDS Rx, integrating more than 200 U.S. locations into its Life Sciences and Healthcare business.

UPS Healthcare invested $48 million in 27 temperature-controlled freight cross-dock facilities worldwide in 2026, expanding cold chain capacity across global markets.

For pharma manufacturers, cold chain consolidation affects launch planning, lane redundancy, chain of custody, service levels, and business continuity.

Technology and Digital Infrastructure Consolidation

Consolidation is not limited to physical assets. It also includes the digital and process infrastructure behind pharma operations. Thermo Fisher completed its acquisition of Solventum’s Purification and Filtration business for approximately $4.0 billion, expanding capabilities in biologics development and manufacturing workflows.

For pharma manufacturers, this means digital transformation must now include partner systems, quality data, manufacturing data, logistics events, and external capacity visibility.

What Consolidation Means for Pharma Manufacturers

The benefits are real. Consolidated partners may offer larger capacity, broader coverage, stronger compliance systems, and more mature technology platforms. For a pharma manufacturer, that can simplify some aspects of supplier management and reduce fragmentation.

But the risk is also real. Fewer partners may mean less negotiating leverage, more dependency on major networks, and greater exposure if one large partner experiences a quality issue, cyber incident, labor shortage, capacity constraint, or integration disruption. A consolidated partner can be stronger, but it can also become a single point of failure.

This is especially important as policymakers focus on supply resilience. The EU Critical Medicines Act provisional agreement in May 2026 aims to diversify critical medicine supply chains, support collaborative procurement, and strengthen manufacturing capacity for critical medicines and active ingredients in the EU. In the U.S., FDA’s PreCheck Pilot Program is designed to strengthen domestic drug manufacturing and improve the resilience of the U.S. drug supply chain through earlier FDA engagement for new manufacturing facilities.

Digital Transformation Priorities for a Consolidated Pharma Supply Chain

A consolidated pharma supply chain is harder to manage without strong digital infrastructure. Pharma manufacturers need visibility across internal and external operations, especially when CMOs, CDMOs, 3PLs, distributors, and specialty partners control key parts of execution.

This is where SCW’s positioning matters. Pharma manufacturers do not only need a technology roadmap. They need an operating model that connects digital supply chain, digital factory, Track and Trace, RPA, AI readiness, and process excellence.

2026 Action Plan for Pharma Executives

Pharma executives should treat consolidation as both an opportunity and a risk. The right response is not to avoid large partners. The right response is to manage them with better data, clearer governance, and stronger scenario planning.

Conclusion

By the end of 2026, pharma supply chain consolidation is no longer a general market trend. It is a direct strategic issue for pharma manufacturers. CDMO networks are growing, cold chain providers are expanding, distributors are moving deeper into specialty care, and digital infrastructure is becoming part of competitive advantage.

For pharma executives, the goal is not simply to track deals. The goal is to understand how consolidation changes capacity access, partner dependency, risk exposure, and transformation priorities. Manufacturers that act early can use consolidation to improve resilience. Manufacturers that wait may find themselves dependent on fewer partners, with limited visibility and slower response when disruptions occur.